Recent clinical and preclinical evidence suggests that psychedelics and entactogens may
produce both rapid and sustained therapeutic effects across several indications. Currently …

Modern psychedelic research remains in an early phase, and the eventual introduction of
psychedelics into clinical practice remains in doubt. In this piece, we discuss the role of …

The unfortunate reality of the mental health crisis plaguing much of the world, in tandem with
and exacerbated by the COVID-19 pandemic [1–3], highlights the limited effective …

Psychedelic or ecodelic medicines (eg, psilocybin, ayahuasca, iboga) for the care and
treatment of addiction, post‐traumatic stress disorder, cancer, cluster headaches, anxiety …

Background: Despite the growth of psychedelic research, psychedelic-assisted group
psychotherapy (PAGP) has received little attention in comparison to individual psychedelic …

In response to a recent call to rid psychedelic science of the concept of mystical experience,
we argue that acknowledging the varieties and weirdness of psychedelic experiences …

Psilocybin is the most researched classic psychedelic for Treatment-Resistant Depression
(TRD). While optimizing set and setting are considered essential for efficacy and safety …

While the literature on psychedelic medicine emphasizes the importance of set and setting
alongside the quality of subjective drug effects for therapeutic efficacy, few scholars have …

The ethical value—and to some scholars, necessity—of providing trial patients with post-trial
access (PTA) to an investigational drug has been subject to significant attention in the field …

In the 2010s, psychopharmacological research and development experienced a crisis: since
no genuinely new drugs for the treatment of mental illness had been successfully developed …